K
Klaus Pantel
Researcher at University of Hamburg
Publications - 566
Citations - 36666
Klaus Pantel is an academic researcher from University of Hamburg. The author has contributed to research in topics: Circulating tumor cell & Cancer. The author has an hindex of 90, co-authored 486 publications receiving 29848 citations.
Papers
More filters
Book ChapterDOI
Pathophysiology of Tumor Cell Release into the Circulation and Characterization of CTC.
TL;DR: The traditional model of metastatic progression postulates that the ability to form distant metastases is driven by random mutations in cells of the primary tumor, but this model is challenged by new findings.
Journal ArticleDOI
191 DETECT III – a Multicenter, Randomized, Phase III Study to Compare Standard Therapy Alone Versus Standard Therapy Plus Lapatinib in Patients with Initially HER2-negative Metastatic Breast Cancer and HER2-positive Circulating Tumor Cells
C Melcher,Wolfgang Janni,Brigitte Rack,Volkmar Müller,Andreas Schneeweiss,Klaus Pantel,Erich-Franz Solomayer,Bahriye Aktas,Peter A. Fasching,Tanja Fehm +9 more
Journal ArticleDOI
Metastatic Breast Cancer Recurrence after Bone Fractures
TL;DR: Bone fracture after breast cancer diagnosis was associated with an increased metastasis risk and the highest risk for metastasis was observed in patients with subsequent bone metastasis, followed by distant non-bone metastasis and lymph node metastasis.
Journal ArticleDOI
Liquid biopsy: blood‐based analyses of circulating cell‐free DNA in xenografts
I. Heidrich,Klaus Pantel +1 more
TL;DR: The report of Sauer et al (2022) demonstrates the feasibility of longitudinal monitoring of disease burden and response using ctDNA from dried blood spots in xenograft models.
Journal ArticleDOI
HER2 expression on circulating tumor cells (CTC) in patients with early HER2-positive breast cancer: Results of the German SUCCESS B trial.
Bernadette Anna Sophia Jaeger,Brigitte Rack,Julia Neugebauer,Ulrich Andergassen,C Melcher,Doraid Mouarrawy,Gabriele Ziemendorff,Michael R. Clemens,Ekkehard von Abel,Georg Heinrich,Katharina Schueller,Andreas Schneeweiss,Werner Lichtenegger,Matthias W. Beckmann,Klaus Pantel,Harald Sommer,Klaus Friese,Wolfgang Janni +17 more
TL;DR: The Her2-status of CTC was prospectively evaluated in the German multicenter SUCCESS B study and the results confirmed that CTC-positivity is low compared to other breast cancer patients receiving adjuvant treatment with Trastuzumab.